Avalo Therapeutics (Nasdaq: AVTX) announced that CEO Dr. Garry Neil will speak on the “Honing in on Hidradenitis” panel at the virtual BTIG Biotechnology Conference on July 29, 2026 at 10:30 a.m. ET. The company will also hold one-on-one investor meetings and provide live and archived webcasts via its investor relations website.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market reaction after Biotechnology conference participation: AVTX -3.56% in the Jul 22 session
-3.56%
2 alerts
-3.56%Session close to close
$957.22MMarket Cap
0.2xRel. Volume
In the Jul 22 session, AVTX declined 3.56%, reflecting a moderate negative market reaction.
Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
A prior conference-participation notice was followed by -3.56% over 24 hours, giving this scheduling...
Analysis
A prior conference-participation notice was followed by -3.56% over 24 hours, giving this scheduling announcement a directly comparable historical reference. Recent insider activity was Net Selling; an S-3 resale registration was not effective and Avalo will not receive proceeds.
Key Figures
Announcement date:July 22, 2026Conference date:July 29, 2026Panel time:10:30 am ET+2 more
Employee received a 34,000-share stock option inducement award
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Avalo's recent event reactions were mixed, including a negative reaction to a prior investor-forum participation announcement despite the comparable event type.
"developing therapeutics targeting the IL-1β pathway"
A signaling chain of proteins and cells driven by the molecule interleukin-1 beta (IL-1β) that triggers and sustains inflammation in the body. Think of it as a biological thermostat and alarm system: when IL-1β is released it amplifies immune responses and can drive symptoms in many diseases, making it a common drug target whose success or failure can affect the value of companies developing therapies or diagnostics.
hidradenitis suppurativamedical
"in a Phase 2 clinical trial in hidradenitis suppurativa"
A chronic skin disease marked by recurring, painful lumps and tunnels under the skin that often leak and leave scars; it behaves like a slow-burning, recurring infection in areas with many sweat glands. For investors, it matters because the condition has few consistently effective treatments and causes long-term healthcare use, making successful new drugs, devices, or diagnostics potentially high-value opportunities while also carrying clinical-trial, regulatory and reimbursement risks.
phase 2 clinical trialmedical
"Positive topline data was recently reported for abdakibart in a Phase 2 clinical trial"
A phase 2 clinical trial is a research study that tests a new medical treatment or drug to see if it is effective and safe for a specific condition. It involves a larger group of people than earlier trials and helps determine whether the treatment should move forward to more extensive testing. For investors, successful phase 2 results can signal potential for future approval and commercial success, while setbacks may indicate challenges ahead.
monoclonal antibodymedical
"ab ialah an anti-IL-1β monoclonal antibody (mAb)"
A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.
WAYNE, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will participate in the “Honing in on Hidradenitis” panel at the virtual BTIG Biotechnology Conference on Wednesday, July 29, 2026, at 10:30 am ET. Management will also host one-on-one investor meetings during the conference.
Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Our lead asset, abdakibart, is an anti-IL-1β monoclonal antibody (mAb). Positive topline data was recently reported for abdakibart in a Phase 2 clinical trial in hidradenitis suppurativa (HS). In addition to HS, we’re exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. We are also advancing AVTX-010, a long-acting next-generation anti-IL-1β mAb designed to extend dosing intervals and build upon the differentiated profile established by abdakibart. For more information about Avalo, please visit www.avalotx.com.
For media and investor inquiries
Christopher Sullivan, CFO Avalo Therapeutics, Inc. ir@avalotx.com 410-803-6793
When will Avalo Therapeutics (AVTX) present at the BTIG Biotechnology Conference in 2026?
Avalo Therapeutics will participate in the BTIG Biotechnology Conference on Wednesday, July 29, 2026, at 10:30 a.m. ET. According to Avalo Therapeutics, CEO Dr. Garry Neil will join the “Honing in on Hidradenitis” virtual panel session during the event.
How can investors access Avalo Therapeutics (AVTX) webcast for the BTIG Biotechnology Conference?
Investors can access Avalo Therapeutics’ live and replay webcasts through the “News / Events” section of its investor relations website. According to Avalo Therapeutics, an archived replay of the conference webcast will remain available for at least 30 days after the event.
Will Avalo Therapeutics (AVTX) hold one-on-one investor meetings during the July 29, 2026 BTIG conference?
Yes, Avalo Therapeutics management will host one-on-one investor meetings during the virtual BTIG Biotechnology Conference. According to Avalo Therapeutics, these meetings will accompany CEO Dr. Garry Neil’s participation on the hidradenitis-focused panel at the July 29, 2026 event.
What IL-1β pipeline programs will Avalo Therapeutics (AVTX) highlight around the BTIG Biotechnology Conference?
Avalo focuses on IL-1β pathway therapies, including abdakibart and AVTX-010. According to Avalo Therapeutics, abdakibart showed positive Phase 2 topline data in hidradenitis suppurativa, and AVTX-010 is a long-acting next-generation anti-IL-1β monoclonal antibody in development.
What did Avalo Therapeutics (AVTX) recently report about abdakibart for hidradenitis suppurativa?
Avalo Therapeutics recently reported positive topline Phase 2 data for abdakibart in hidradenitis suppurativa. According to Avalo Therapeutics, abdakibart is an anti-IL-1β monoclonal antibody, and the company is also exploring additional immune-mediated inflammatory disease indications with unmet medical needs.
